Considering that it was difficult to distinguish CAFs with different phenotypes due to a lack of definitive biomarkers and signaling pathways, it was more practical to target SLIT2/ROBO1, as the blocking of SLIT2 binding to ROBO1 by a soluble ROBO1 antagonist significantly attenuated SLIT2-induced GC metastasis. This evidence concerns the gene ROBO1 and gastric cancer.